The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-Invasive Cancer Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Non-Invasive Cancer Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Non-Invasive Cancer Diagnostics market size is estimated to be worth US$ 111670 million in 2021 and is forecast to a readjusted size of USD 144320 million by 2028 with a CAGR of 3.7% during review period. Blood accounting for % of the Non-Invasive Cancer Diagnostics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While CTCs segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Non-Invasive Cancer Diagnostics include Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Cancer, Genetics Inc, and BIOVIEW Inc, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Non-Invasive Cancer Diagnostics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CTCs
CTNAS
Exosomes
Market segment by Application, can be divided into
Blood
Urine
Saliva
Market segment by players, this report covers
Gen-Probe Inc
Digene Corporation
Quest Diagnostics Inc
Cancer, Genetics Inc
BIOVIEW Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
A&G Pharmaceutical
Affymetrix Inc
Precision Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Non-Invasive Cancer Diagnostics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Non-Invasive Cancer Diagnostics, with revenue, gross margin and global market share of Non-Invasive Cancer Diagnostics from 2019 to 2022.
Chapter 3, the Non-Invasive Cancer Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Non-Invasive Cancer Diagnostics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Non-Invasive Cancer Diagnostics research findings and conclusion, appendix and data source.
Geographical Area
Global
The Non-Invasive Cancer Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Non-Invasive Cancer Diagnostics market size is estimated to be worth US$ 111670 million in 2021 and is forecast to a readjusted size of USD 144320 million by 2028 with a CAGR of 3.7% during review period. Blood accounting for % of the Non-Invasive Cancer Diagnostics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While CTCs segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Non-Invasive Cancer Diagnostics include Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Cancer, Genetics Inc, and BIOVIEW Inc, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Non-Invasive Cancer Diagnostics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CTCs
CTNAS
Exosomes
Market segment by Application, can be divided into
Blood
Urine
Saliva
Market segment by players, this report covers
Gen-Probe Inc
Digene Corporation
Quest Diagnostics Inc
Cancer, Genetics Inc
BIOVIEW Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
A&G Pharmaceutical
Affymetrix Inc
Precision Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Non-Invasive Cancer Diagnostics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Non-Invasive Cancer Diagnostics, with revenue, gross margin and global market share of Non-Invasive Cancer Diagnostics from 2019 to 2022.
Chapter 3, the Non-Invasive Cancer Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Non-Invasive Cancer Diagnostics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Non-Invasive Cancer Diagnostics research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Non-Invasive Cancer Diagnostics
1.2 Classification of Non-Invasive Cancer Diagnostics by Type
1.2.1 Overview: Global Non-Invasive Cancer Diagnostics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Non-Invasive Cancer Diagnostics Revenue Market Share by Type in 2021
1.2.3 CTCs
1.2.4 CTNAS
1.2.5 Exosomes
1.3 Global Non-Invasive Cancer Diagnostics Market by Application
1.3.1 Overview: Global Non-Invasive Cancer Diagnostics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Blood
1.3.3 Urine
1.3.4 Saliva
1.4 Global Non-Invasive Cancer Diagnostics Market Size & Forecast
1.5 Global Non-Invasive Cancer Diagnostics Market Size and Forecast by Region
1.5.1 Global Non-Invasive Cancer Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Non-Invasive Cancer Diagnostics Market Size by Region, (2017-2022)
1.5.3 North America Non-Invasive Cancer Diagnostics Market Size and Prospect (2017-2028)
1.5.4 Europe Non-Invasive Cancer Diagnostics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size and Prospect (2017-2028)
1.5.6 South America Non-Invasive Cancer Diagnostics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Non-Invasive Cancer Diagnostics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-Invasive Cancer Diagnostics Market Drivers
1.6.2 Non-Invasive Cancer Diagnostics Market Restraints
1.6.3 Non-Invasive Cancer Diagnostics Trends Analysis
2 Company Profiles
2.1 Gen-Probe Inc
2.1.1 Gen-Probe Inc Details
2.1.2 Gen-Probe Inc Major Business
2.1.3 Gen-Probe Inc Non-Invasive Cancer Diagnostics Product and Solutions
2.1.4 Gen-Probe Inc Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Gen-Probe Inc Recent Developments and Future Plans
2.2 Digene Corporation
2.2.1 Digene Corporation Details
2.2.2 Digene Corporation Major Business
2.2.3 Digene Corporation Non-Invasive Cancer Diagnostics Product and Solutions
2.2.4 Digene Corporation Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Digene Corporation Recent Developments and Future Plans
2.3 Quest Diagnostics Inc
2.3.1 Quest Diagnostics Inc Details
2.3.2 Quest Diagnostics Inc Major Business
2.3.3 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Product and Solutions
2.3.4 Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Quest Diagnostics Inc Recent Developments and Future Plans
2.4 Cancer, Genetics Inc
2.4.1 Cancer, Genetics Inc Details
2.4.2 Cancer, Genetics Inc Major Business
2.4.3 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Product and Solutions
2.4.4 Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Cancer, Genetics Inc Recent Developments and Future Plans
2.5 BIOVIEW Inc
2.5.1 BIOVIEW Inc Details
2.5.2 BIOVIEW Inc Major Business
2.5.3 BIOVIEW Inc Non-Invasive Cancer Diagnostics Product and Solutions
2.5.4 BIOVIEW Inc Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 BIOVIEW Inc Recent Developments and Future Plans
2.6 AVIVA Biosciences Corporation
2.6.1 AVIVA Biosciences Corporation Details
2.6.2 AVIVA Biosciences Corporation Major Business
2.6.3 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Product and Solutions
2.6.4 AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 AVIVA Biosciences Corporation Recent Developments and Future Plans
2.7 Laboratory Corporation of America Holdings (LabCorp)
2.7.1 Laboratory Corporation of America Holdings (LabCorp) Details
2.7.2 Laboratory Corporation of America Holdings (LabCorp) Major Business
2.7.3 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Product and Solutions
2.7.4 Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Laboratory Corporation of America Holdings (LabCorp) Recent Developments and Future Plans
2.8 A&G Pharmaceutical
2.8.1 A&G Pharmaceutical Details
2.8.2 A&G Pharmaceutical Major Business
2.8.3 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Product and Solutions
2.8.4 A&G Pharmaceutical Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 A&G Pharmaceutical Recent Developments and Future Plans
2.9 Affymetrix Inc
2.9.1 Affymetrix Inc Details
2.9.2 Affymetrix Inc Major Business
2.9.3 Affymetrix Inc Non-Invasive Cancer Diagnostics Product and Solutions
2.9.4 Affymetrix Inc Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Affymetrix Inc Recent Developments and Future Plans
2.10 Precision Therapeutics
2.10.1 Precision Therapeutics Details
2.10.2 Precision Therapeutics Major Business
2.10.3 Precision Therapeutics Non-Invasive Cancer Diagnostics Product and Solutions
2.10.4 Precision Therapeutics Non-Invasive Cancer Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Precision Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Non-Invasive Cancer Diagnostics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Non-Invasive Cancer Diagnostics Players Market Share in 2021
3.2.2 Top 10 Non-Invasive Cancer Diagnostics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Non-Invasive Cancer Diagnostics Players Head Office, Products and Services Provided
3.4 Non-Invasive Cancer Diagnostics Mergers & Acquisitions
3.5 Non-Invasive Cancer Diagnostics New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Non-Invasive Cancer Diagnostics Revenue and Market Share by Type (2017-2022)
4.2 Global Non-Invasive Cancer Diagnostics Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Non-Invasive Cancer Diagnostics Revenue Market Share by Application (2017-2022)
5.2 Global Non-Invasive Cancer Diagnostics Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Non-Invasive Cancer Diagnostics Revenue by Type (2017-2028)
6.2 North America Non-Invasive Cancer Diagnostics Revenue by Application (2017-2028)
6.3 North America Non-Invasive Cancer Diagnostics Market Size by Country
6.3.1 North America Non-Invasive Cancer Diagnostics Revenue by Country (2017-2028)
6.3.2 United States Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
6.3.3 Canada Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
6.3.4 Mexico Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Non-Invasive Cancer Diagnostics Revenue by Type (2017-2028)
7.2 Europe Non-Invasive Cancer Diagnostics Revenue by Application (2017-2028)
7.3 Europe Non-Invasive Cancer Diagnostics Market Size by Country
7.3.1 Europe Non-Invasive Cancer Diagnostics Revenue by Country (2017-2028)
7.3.2 Germany Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
7.3.3 France Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
7.3.5 Russia Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
7.3.6 Italy Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Non-Invasive Cancer Diagnostics Revenue by Type (2017-2028)
8.2 Asia-Pacific Non-Invasive Cancer Diagnostics Revenue by Application (2017-2028)
8.3 Asia-Pacific Non-Invasive Cancer Diagnostics Market Size by Region
8.3.1 Asia-Pacific Non-Invasive Cancer Diagnostics Revenue by Region (2017-2028)
8.3.2 China Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
8.3.3 Japan Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
8.3.4 South Korea Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
8.3.5 India Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
8.3.7 Australia Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Non-Invasive Cancer Diagnostics Revenue by Type (2017-2028)
9.2 South America Non-Invasive Cancer Diagnostics Revenue by Application (2017-2028)
9.3 South America Non-Invasive Cancer Diagnostics Market Size by Country
9.3.1 South America Non-Invasive Cancer Diagnostics Revenue by Country (2017-2028)
9.3.2 Brazil Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
9.3.3 Argentina Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Non-Invasive Cancer Diagnostics Revenue by Type (2017-2028)
10.2 Middle East & Africa Non-Invasive Cancer Diagnostics Revenue by Application (2017-2028)
10.3 Middle East & Africa Non-Invasive Cancer Diagnostics Market Size by Country
10.3.1 Middle East & Africa Non-Invasive Cancer Diagnostics Revenue by Country (2017-2028)
10.3.2 Turkey Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
10.3.4 UAE Non-Invasive Cancer Diagnostics Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Non-Invasive Cancer Diagnostics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Non-Invasive Cancer Diagnostics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Non-Invasive Cancer Diagnostics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Non-Invasive Cancer Diagnostics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Region (2023-2028)
Table 6. Gen-Probe Inc Corporate Information, Head Office, and Major Competitors
Table 7. Gen-Probe Inc Major Business
Table 8. Gen-Probe Inc Non-Invasive Cancer Diagnostics Product and Solutions
Table 9. Gen-Probe Inc Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Digene Corporation Corporate Information, Head Office, and Major Competitors
Table 11. Digene Corporation Major Business
Table 12. Digene Corporation Non-Invasive Cancer Diagnostics Product and Solutions
Table 13. Digene Corporation Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Quest Diagnostics Inc Corporate Information, Head Office, and Major Competitors
Table 15. Quest Diagnostics Inc Major Business
Table 16. Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Product and Solutions
Table 17. Quest Diagnostics Inc Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Cancer, Genetics Inc Corporate Information, Head Office, and Major Competitors
Table 19. Cancer, Genetics Inc Major Business
Table 20. Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Product and Solutions
Table 21. Cancer, Genetics Inc Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. BIOVIEW Inc Corporate Information, Head Office, and Major Competitors
Table 23. BIOVIEW Inc Major Business
Table 24. BIOVIEW Inc Non-Invasive Cancer Diagnostics Product and Solutions
Table 25. BIOVIEW Inc Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. AVIVA Biosciences Corporation Corporate Information, Head Office, and Major Competitors
Table 27. AVIVA Biosciences Corporation Major Business
Table 28. AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Product and Solutions
Table 29. AVIVA Biosciences Corporation Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Laboratory Corporation of America Holdings (LabCorp) Corporate Information, Head Office, and Major Competitors
Table 31. Laboratory Corporation of America Holdings (LabCorp) Major Business
Table 32. Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Product and Solutions
Table 33. Laboratory Corporation of America Holdings (LabCorp) Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. A&G Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 35. A&G Pharmaceutical Major Business
Table 36. A&G Pharmaceutical Non-Invasive Cancer Diagnostics Product and Solutions
Table 37. A&G Pharmaceutical Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Affymetrix Inc Corporate Information, Head Office, and Major Competitors
Table 39. Affymetrix Inc Major Business
Table 40. Affymetrix Inc Non-Invasive Cancer Diagnostics Product and Solutions
Table 41. Affymetrix Inc Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Precision Therapeutics Corporate Information, Head Office, and Major Competitors
Table 43. Precision Therapeutics Major Business
Table 44. Precision Therapeutics Non-Invasive Cancer Diagnostics Product and Solutions
Table 45. Precision Therapeutics Non-Invasive Cancer Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Global Non-Invasive Cancer Diagnostics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 47. Global Non-Invasive Cancer Diagnostics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 48. Breakdown of Non-Invasive Cancer Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Non-Invasive Cancer Diagnostics Players Head Office, Products and Services Provided
Table 50. Non-Invasive Cancer Diagnostics Mergers & Acquisitions in the Past Five Years
Table 51. Non-Invasive Cancer Diagnostics New Entrants and Expansion Plans
Table 52. Global Non-Invasive Cancer Diagnostics Revenue (USD Million) by Type (2017-2022)
Table 53. Global Non-Invasive Cancer Diagnostics Revenue Share by Type (2017-2022)
Table 54. Global Non-Invasive Cancer Diagnostics Revenue Forecast by Type (2023-2028)
Table 55. Global Non-Invasive Cancer Diagnostics Revenue by Application (2017-2022)
Table 56. Global Non-Invasive Cancer Diagnostics Revenue Forecast by Application (2023-2028)
Table 57. North America Non-Invasive Cancer Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 58. North America Non-Invasive Cancer Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 59. North America Non-Invasive Cancer Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 60. North America Non-Invasive Cancer Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 61. North America Non-Invasive Cancer Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 62. North America Non-Invasive Cancer Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 63. Europe Non-Invasive Cancer Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 64. Europe Non-Invasive Cancer Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 65. Europe Non-Invasive Cancer Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 66. Europe Non-Invasive Cancer Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 67. Europe Non-Invasive Cancer Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 68. Europe Non-Invasive Cancer Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 69. Asia-Pacific Non-Invasive Cancer Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 70. Asia-Pacific Non-Invasive Cancer Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 71. Asia-Pacific Non-Invasive Cancer Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 72. Asia-Pacific Non-Invasive Cancer Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 73. Asia-Pacific Non-Invasive Cancer Diagnostics Revenue by Region (2017-2022) & (USD Million)
Table 74. Asia-Pacific Non-Invasive Cancer Diagnostics Revenue by Region (2023-2028) & (USD Million)
Table 75. South America Non-Invasive Cancer Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 76. South America Non-Invasive Cancer Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 77. South America Non-Invasive Cancer Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 78. South America Non-Invasive Cancer Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 79. South America Non-Invasive Cancer Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 80. South America Non-Invasive Cancer Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 81. Middle East & Africa Non-Invasive Cancer Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 82. Middle East & Africa Non-Invasive Cancer Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 83. Middle East & Africa Non-Invasive Cancer Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 84. Middle East & Africa Non-Invasive Cancer Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 85. Middle East & Africa Non-Invasive Cancer Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 86. Middle East & Africa Non-Invasive Cancer Diagnostics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Non-Invasive Cancer Diagnostics Picture
Figure 2. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Type in 2021
Figure 3. CTCs
Figure 4. CTNAS
Figure 5. Exosomes
Figure 6. Non-Invasive Cancer Diagnostics Revenue Market Share by Application in 2021
Figure 7. Blood Picture
Figure 8. Urine Picture
Figure 9. Saliva Picture
Figure 10. Global Non-Invasive Cancer Diagnostics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 11. Global Non-Invasive Cancer Diagnostics Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Region (2017-2028)
Figure 13. Global Non-Invasive Cancer Diagnostics Revenue Market Share by Region in 2021
Figure 14. North America Non-Invasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Europe Non-Invasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Asia-Pacific Non-Invasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. South America Non-Invasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Middle East and Africa Non-Invasive Cancer Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Non-Invasive Cancer Diagnostics Market Drivers
Figure 20. Non-Invasive Cancer Diagnostics Market Restraints
Figure 21. Non-Invasive Cancer Diagnostics Market Trends
Figure 22. Gen-Probe Inc Recent Developments and Future Plans
Figure 23. Digene Corporation Recent Developments and Future Plans
Figure 24. Quest Diagnostics Inc Recent Developments and Future Plans
Figure 25. Cancer, Genetics Inc Recent Developments and Future Plans
Figure 26. BIOVIEW Inc Recent Developments and Future Plans
Figure 27. AVIVA Biosciences Corporation Recent Developments and Future Plans
Figure 28. Laboratory Corporation of America Holdings (LabCorp) Recent Developments and Future Plans
Figure 29. A&G Pharmaceutical Recent Developments and Future Plans
Figure 30. Affymetrix Inc Recent Developments and Future Plans
Figure 31. Precision Therapeutics Recent Developments and Future Plans
Figure 32. Global Non-Invasive Cancer Diagnostics Revenue Share by Players in 2021
Figure 33. Non-Invasive Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 34. Global Top 3 Players Non-Invasive Cancer Diagnostics Revenue Market Share in 2021
Figure 35. Global Top 10 Players Non-Invasive Cancer Diagnostics Revenue Market Share in 2021
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 37. Global Non-Invasive Cancer Diagnostics Revenue Share by Type in 2021
Figure 38. Global Non-Invasive Cancer Diagnostics Market Share Forecast by Type (2023-2028)
Figure 39. Global Non-Invasive Cancer Diagnostics Revenue Share by Application in 2021
Figure 40. Global Non-Invasive Cancer Diagnostics Market Share Forecast by Application (2023-2028)
Figure 41. North America Non-Invasive Cancer Diagnostics Sales Market Share by Type (2017-2028)
Figure 42. North America Non-Invasive Cancer Diagnostics Sales Market Share by Application (2017-2028)
Figure 43. North America Non-Invasive Cancer Diagnostics Revenue Market Share by Country (2017-2028)
Figure 44. United States Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Canada Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Mexico Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Europe Non-Invasive Cancer Diagnostics Sales Market Share by Type (2017-2028)
Figure 48. Europe Non-Invasive Cancer Diagnostics Sales Market Share by Application (2017-2028)
Figure 49. Europe Non-Invasive Cancer Diagnostics Revenue Market Share by Country (2017-2028)
Figure 50. Germany Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific Non-Invasive Cancer Diagnostics Sales Market Share by Type (2017-2028)
Figure 56. Asia-Pacific Non-Invasive Cancer Diagnostics Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific Non-Invasive Cancer Diagnostics Revenue Market Share by Region (2017-2028)
Figure 58. China Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. South Korea Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Non-Invasive Cancer Diagnostics Sales Market Share by Type (2017-2028)
Figure 65. South America Non-Invasive Cancer Diagnostics Sales Market Share by Application (2017-2028)
Figure 66. South America Non-Invasive Cancer Diagnostics Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East and Africa Non-Invasive Cancer Diagnostics Sales Market Share by Type (2017-2028)
Figure 70. Middle East and Africa Non-Invasive Cancer Diagnostics Sales Market Share by Application (2017-2028)
Figure 71. Middle East and Africa Non-Invasive Cancer Diagnostics Revenue Market Share by Country (2017-2028)
Figure 72. Turkey Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. UAE Non-Invasive Cancer Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
